Genenta Science S.p.A. (GNTA )

Currency in USD Disclaimer
$6.2 +$2.97 (91.95%)
Closed 10/24/2025
$5.68
$10
$2.56
$10

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol GNTA
  • Company Genenta Science S.p.A.
  • Price $6.2
  • Changes Percentage 91.95
  • Change 2.97
  • Day Low $5.68
  • Day High $10
  • Year High $10
  • Year Low $2.56
  • Market Cap $118,682,558
  • Price Avg 50 EMA (D) $3.36
  • Price Avg 200 EMA (D) $3.77
  • Exchange NASDAQ
  • Volume 21,920,565
  • Average Volume 350,407
  • Open $9.88
  • Previous Close $3.23
  • EPS -0.55
  • PE -11.27
  • Earnings Announcement 2026-02-25 12:00:00
  • Shares Outstanding $19,142,348

Company brief: GENENTA SCIENCE S.P.A. (GNTA )

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.

GNTA Corporation News

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

October 27, 2025 at 12:30 am ET

globenewswire.com -- MILAN and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that it has entered into a securities purchase agreement with instit...

Income Statement